Murugan Chandran, Lee Hyoryong, Park Sukho
Department of Robotics and Mechatronics Engineering, Multiscale Biomedical Robotics Laboratory, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Republic of Korea.
J Mater Chem B. 2023 Feb 1;11(5):1044-1056. doi: 10.1039/d2tb02382b.
Combinational therapy can improve the effectiveness of cancer treatment by overcoming individual therapy shortcomings, leading to accelerated cancer cell apoptosis. Combinational cancer therapy is attained by a single nanosystem with multiple physicochemical properties providing an efficient synergistic therapy against cancer cells. Herein, we report a folate receptor-targeting dual-therapeutic (photothermal and chemotherapy) core-shell nanoparticle (CSNP) exhibiting a molybdenum disulfide core with a barium titanate shell (MoS@BT) to improve therapeutic efficacy against triple-negative breast cancer (TNBC) MDA-MB-231 cells. A simple hydrothermal approach was used to achieve the MoS@BT CSNPs, and their diameter was calculated to be approximately 180 ± 25 nm. In addition to improving the photothermal efficiency and stability of the MoS@BT CSNPs, their surface was functionalized with polydopamine (PDA) and subsequently modified with folic acid (FA) to achieve enhanced tumour-targeting CSNPs, named MoS@BT-PDA-FA (MBPF). Then, gemcitabine (Gem) was loaded into the MBPF, and its loading and releasing efficacy were calculated to be 17.5 wt% and 64.5 ± 3%, respectively. Moreover, the photothermal conversion efficiency (PCE) of MBPF was estimated to be 35.3%, and it also showed better biocompatibility, which was determined by an MTT assay. The MBPF significantly increased the ambient temperature to 56.3 °C and triggered Gem release inside the TNBC cells when exposed to a near-infrared (NIR) laser (808 nm, 1.5 W cm, 5 min). Notably, the MoS@BT-based nanosystem was used as a photothermal agent and a therapeutic drug-loading container for combating TNBC cells. Benefiting from the combined therapy, MBPF reduced TNBC cell viability to 81.3% due to its efficient synergistic effects. Thus, the proposed tumour-targeting MoS@BT CSNP exhibits high drug loading, better biocompatibility, and improved anticancer efficacy toward TNBC cells due to its dual therapeutic approach in a single system, which opens up a new approach for dual cancer therapy.
联合治疗可以通过克服单一疗法的缺点来提高癌症治疗的有效性，从而加速癌细胞凋亡。联合癌症治疗是通过具有多种物理化学性质的单一纳米系统实现的，该系统能为癌细胞提供高效的协同治疗。在此，我们报道了一种叶酸受体靶向双治疗（光热和化疗）核壳纳米颗粒（CSNP），其具有二硫化钼核和钛酸钡壳（MoS@BT），以提高对三阴性乳腺癌（TNBC）MDA-MB-231细胞的治疗效果。采用简单的水热法制备了MoS@BT CSNP，其直径经计算约为180±25nm。除了提高MoS@BT CSNP的光热效率和稳定性外，其表面还用聚多巴胺（PDA）进行了功能化，随后用叶酸（FA）进行了修饰，以获得增强的肿瘤靶向CSNP，命名为MoS@BT-PDA-FA（MBPF）。然后，将吉西他滨（Gem）负载到MBPF中，其负载率和释放率经计算分别为17.5 wt%和64.5±3%。此外，MBPF的光热转换效率（PCE）估计为35.3%，并且通过MTT试验确定其还表现出更好的生物相容性。当暴露于近红外（NIR）激光（808nm，1.5W/cm，5min）时，MBPF可将环境温度显著提高至56.3°C，并触发TNBC细胞内Gem的释放。值得注意的是，基于MoS@BT的纳米系统用作光热剂和治疗药物负载容器来对抗TNBC细胞。受益于联合治疗，由于其高效的协同作用，MBPF将TNBC细胞活力降低至81.3%。因此，所提出的肿瘤靶向MoS@BT CSNP由于其在单一系统中的双治疗方法，表现出高药物负载、更好的生物相容性以及对TNBC细胞的抗癌效果改善作用，这为双癌症治疗开辟了一条新途径。
